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Phosphodiesterase 4D (PDE4D) is a member of the large superfamily of phosphodiesterases. PDE4D polymorphisms have been
found to associate with ischemic stroke. Proliferation and migration of vascular smooth muscle cells (VSMCs) play a critical role
in the pathogenesis of atherosclerosis. In this study, infection of VSMCs with lentivrius particles carrying shRNA direct against
PDE4D signiﬁcantly inhibited platelet-derived growth factor-induced VSMC proliferation and migration, and the inhibitory
eﬀects were not associatedwith global intracellular cAMP level. Our results implicate that PDE4D has animportant role in VSMC
proliferation and migration which may explain its genetic susceptibility to ischemic stroke.
1.Introduction
Stroke, a complex disease, remains the third common cause
of death behind heart disease and cancer and is the leading
cause of disability in developed countries as well as in China.
Ischemic stroke accounts for up to 80% of all strokes. Both
environmental factors and genetic variants contribute to
stroke. Although several genetic defects have been identiﬁed
in rare forms of stroke, the genetic causes of common forms
of ischemic stroke remain elusive. Recently, PDE4D has been
identiﬁed as the ﬁrst gene linked to common forms of stroke
[1].However,subsequentstudieshaveproducedinconsistent
results for the association [2–9]. Due to the variable results,
several meta-analyses on the gene have been accomplished,
which also drew conﬂicting conclusions [10–13]. Racial
diﬀerences might be responsible for the inconsistent results.
Therefore, experimental studies on function of PDE4D will
help to unveil the puzzle.
PDE4D belongs to a large superfamily of PDEs which
are the only hydrolytic enzymes of cAMP and key signal
transduction molecules in multiple cell types, including vas-
cular smooth muscle cells. Eleven families (PDE1–PDE11)
have been identiﬁed in the large superfamily of PDEs [14].
There arefourmajor families foundinVSMCs:PDE1,PDE5,
PDE3, and PDE4. PDE1 and PDE5 are mainly responsible
for cGMP-hydrolyzing activity, whereas PDE3 and PDE4
contribute to most of cAMP-hydrolyzing activity [15, 16].
PDE4 has four subfamilies: PDE4A, 4B, 4C, and 4D, which
are diﬀerentially localized between cells [17]. PDE4D is
expressed broadly in many kinds of cell [18, 19]. In arterial
VSMCs, PDE4D is dominantly expressed and degrades
second-messenger cAMP[20]. Recent studies suggest that
PDE4D may have a critical role in atherosclerosis. For exam-
ple, PDE4D is largely associated with atherosclerotic stroke
such as cardiogenic and carotid strokes [1]. Furthermore,
a decrease in cAMP level has been found to associate with
increased proliferation and migration of vascular smooth-
muscle cells, the central events in the development of
atherosclerosis [21,22].Moreimportantly,PDE4antagonists
have been shown to signiﬁcantly inhibit smooth-muscle
proliferation in a rat carotid balloon-injury model [23–25].
However, the reagents they used are not the speciﬁc inhibitor
against PDE4D, which makes it hard to determinate the
functional roles of PDE4D isoform in the process. Therefore,2 Stroke Research and Treatment
genetic approach speciﬁcally targeting PDE4D gene such
as use of shRNA to knockdown its expression would be
necessary to address this issue.
The present study was conducted to investigate whether
downregulation of PDE4D can inhibit VSMC proliferation
and migration. Lentivirus particle carrying small hairpin
RNA against PDE4D was applied to speciﬁcally reduce
PDE4D expression in rat aortic smooth muscle cells. We
found that PDE4D silence in rat aortic smooth muscle
cells signiﬁcantly inhibits their proliferation and migration
induced by platelet-derived growth factor (PDGF), and the
inhibition is not associated with global intracellular cAMP
level.
2.Materialsand Methods
2.1. Cell Culture. The human HEK-293T-cell line was
obtained from American Type Culture Collection (ATCC)
and grown in RPMI 1640 supplemented with 10% FBS
(Sigma-Aldrich, St. Louis, MO, USA).
VSMCs were isolated from descending thoracic aorta
of male Sprague-Dawley rats weighed about 150g and
characterized morphologically and immunohistochemically
as described previously [26]. Cells were grown in Dulbecco’s
modiﬁed Eagle’s medium (DMEM), with 10% fetal bovine
serum (FBS), 1mmol/L L-glutamine, 100U/mL penicillin,
and 100μg/mL streptomycin, at 37◦C/5% CO2. Cells were
trypsin passaged after 10 days and then at 95% conﬂuence
(Jinuo Biology and Medicine Company, China). All experi-
ments were performed on cells at passage 4 through 6 and
60% to 90% conﬂuence. In all experiments, the cells were
made quiescent by incubating for 24 hours in serum-free
medium prior to use.
2.2. PDE4D Gene Silence in Rat VMSCs. The lentivirus
vector system used in the experiment was purchased from
Shanghai Genchem Company (Shanghai, China), which was
composed of three plasmids—pGCL-GFP, pHelper1.0, and
pHelper2.0. The plasmid pGCL-GFP had an U6 promoter
and a GFP reporter gene.
The oligonucleotide sequences of four diﬀerent PDE4D-
shRNAs and a control nonsense shRNA are as shown in
Table 1. All shRNAs were synthesized by Shanghai Genchem
Company. These four 21 nucleotide shRNA duplexes from
four diﬀerent parts of the PDE4D mRNA (Gen Bank Acces-
sionno.NM 017032)weredesignedusing speciﬁcguidelines
for designing shRNA hairpins encoded by shRNA expression
vectorsandshRNA expression cassettes ofAmbioncompany.
Of sequences tested for PDE4D knockdown using Western
blot, the sequence locating at 181 achieved the best inter-
fering eﬀect and was subsequently cloned into the shRNA-
pGCL-GFP lentiviral vector. Nonsense shRNA was served as
a control. Infectious viruses were producedby cotransfecting
the lentiviral vectors and packaging constructs into 293FT
cells using Lipofectamine reagent (Invitrogen).
Recombinant lentviruses containing shRNA against
PDE4D and nonsense shRNA were obtained from Genchem
Company. VSMCs were infected with puriﬁed lentivirus at
Table 1: Information of four designed shRNA and nonsense
sequences.
No. Sequences Locates GC %
1 GCGATTATGACCTCTCTCC 181 52.60
2 CCAACCATCCATCAACAAA 368 42.10
3 CCCATGTGCAACCAACCAT 357 52.60
4 CCGGATAATGGAGGAGTTC 1499 52.60
nonsense TTCTCCGAACGTGTCACGT — 52.63
Theno. 1locatingat181achievedthebestinterferingeﬀectaround72%.
an MOI(multiplicitiesof infection) of50to obtain95–100%
eﬃciency, as determined by GFP expression 24 hours after
infection.
2.3. Western Blot. VSMCs were collected and sonicated
by sonicator. Protein was extracted from the lysate and
separated with SDS-PAGE (sodium dodecyl sulfate poly-
acrylamide gel electrohoresis). Following electrophoresis,
proteins were transferred to PVDF membranes, and the
membranes were blocked by incubation with TBST (Tris
Buﬀered Saline Tween) containing 5% skim milk for 1 hour.
Blotswereincubatedwithanappropriatedilutionofprimary
antibodies against rat PDE4D (Abcam) and α-actin (San-
tacruz) for 2 hours and rinsed three times with TBST. Rinsed
blots were incubated with second antibodies (Santacruz)
for 2 hours and rinsed with TBST. Immunoreactivity was
detected by chemiluminescence (Amersham ECL plus kit).
2.4. Cell Viability and Proliferation. Cell viability and pro-
liferation was measured by assessing mitochondrial activity
of VSMCs using an MTT kit (Sigma). Cells were growth-
arrested in serum-free medium for 24 hours and then cul-
tured in medium with 0.5% FBS and PDGF-BB (Pepro Tech,
20ng/mL) for 24 hours before addition of MTT (5mg/mL,
Boli Company, China). The MTT solution (5mg/mL MTT
in medium without phenol red) was added to the culture
solution to a volume equal to 10%. Further incubation at
37◦C for four hours yielded purple MTT formazan crystals.
Once solubilizedwith DMSO,the absorbance in each culture
was measured at 570nm with the background (650nm)
subtracted.
2.5. Migration Assay. VSMCs migration assays were per-
formed using a modiﬁed Boyden’s chamber ﬁtted with
8-μm pore membrane (Corning). Brieﬂy, VSMCs were
resuspended in serum-free medium to a concentration of
1×105 cells/mL. A volume of 200μL of cell suspension was
added to the upper wells of the Boyden’s chamber, and 0.5%
FBS-medium with or without PDGF (20ng/mL) was added
to the lower chamber. Migration was allowed to proceed for
12 hours in a37
◦C, 5% CO2, humidiﬁed atmosphere. Then,
cells remaining on the upper surface of the membrane were
scraped oﬀ with cotton sticks. Cells that had migrated to the
lowersurface were ﬁxedwithparaformaldehyde(Guangzhou
Reagentfactory)andstainedwithDAPI(Jackson)andcrystal
violet (Weijia Technical Company, Guangzhou). MigrationStroke Research and Treatment 3
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Figure 1: Knockdown of endogenous PDE4D expression by lentiviral vector-mediated shRNA in VSMCs. VSMCs were infected with the
same amount (PDE4D-shRNA: 12.5 μL, nonsense shRNA: 6.25 μL) of lentivirus particles carrying either shRNA (titer 4×108 TU/mL)
against PDE4D or nonsense shRNA (titer 8×108 TU/mL). PDE4D protein expression was determined at 48 hours postinfection. Values
represent means ± SEM. E: inhibition of PDE4D expression in PDE4D shRNA-tranfected cells was calculated relative to the PDE4D
expressionincellstranfected withthecontrolnonsenseshRNA.Sh-GFP:lentivirusparticlescarryingnonsenseshRNA,Sh-PDE4D:lentivirus
particles carrying shRNA against PDE4D.
capacity was identiﬁed by the average number of stained
cells in six random ﬁelds of view (magniﬁcation ×400) per
membrane. The experiment was repeated three times.
2.6. Measurement of cAMP. The intracellular cAMP levels
in cultured VSMCs were determined by cAMP RIA test
kit purchased from Shanghai Chinese Medicine Univer-
sity following the kit instruction (Shanghai, China). The
detection limit of cAMP was 0.08pmol/L, and the inter-
and intra-assay coeﬃcients of variation were <10%. Starved
cells were incubated in 0.5% FBS-medium with or without
PDGF (20ng/mL) for another 24 hours. Cells were lysed
in acid/alcohol (750mL of ethanol: 248.5mL of double-
distilled H2O:1.5mL of concentrated HCL) containing
IBMX(500μM).Thelysatewasacetylatedwith10μLvolume
of a 1:2 (v:v) mixture of acetic anhydride plus triethy-
lamine. After acetylation, samples were preincubated for 1
hour at room temperature with 100μLa n t i - c A M Pb e f o r e
adding 100μL 125I-cAMP and incubating for overnight at
4◦C. After separation with adsorbing materials, the samples
were centrifuged at 3000rpm for 15min. The supernatant
ﬂuids were aspirated, the radioactivity of precipitates was
counted by γ-counter, and cAMP levels were determined by
comparison to a standard curve.
2.7. Statistical Analysis. All data were processed with SPSS
12.0 statistical software. All results are expressed as means
± SEM. Data were analyzed using a one-way ANOVA and
Student-Newman-Keuls tests for multiple comparisons. In
all cases, P ≤ .05 was taken as statistically signiﬁcant.
3.Results
3.1. Screening of shRNAs for Gene Silence of PDE4D after
Infection with Lentivrius Particles Carrying shRNA against
PDE4D in VSMCs. To determine PDE4D gene silencing
eﬀect, VSMCs were transiently transfected with lentivrius
particles carrying shRNAs against PDE4D. Four diﬀerent
shRNA duplexes, named as no. 1, no. 2, no. 3, and no.
4, were designed to target diﬀerent regions of rat PDE4D
(NM 017032):startsitesof181,368,357,and1499(Table 1).
All four diﬀerent shRNAs could inhibit PDE4D at both tran-
scription and protein levels as determined by real-time RT-
PCR and western blotting (data not shown). These shRNA
duplexes showed varying degrees of PDE4D gene silencing
eﬃciency ranging from 53% to 72% (data not shown).
The no. 1 with sequence locating at 181 achieved the best
interfering eﬀect around 72% and was subsequently cloned
into the shRNA-pGCL-GFP lentiviral vector (Figure 1). The
nonsense shRNA treatment did not signiﬁcantly alter the
levelsofPDE4Dtranscript andproteinand wassubsequently
cloned into the shRNA- pGCL-GFP lentiviral vector as a
shRNA control (Figure 1).
3.2. PDE4D Gene Silence Inhibits PDGF-Induced VSMC
Proliferation without Aﬀecting Cell Viability. To determine
whether PDE4D participates in PDGF-induced VSMC pro-
liferation, we treated cells with PDGF and the proliferation
was assayed using MTT at 24 hours after PDGF stimulation.
As shown in Figure 2, noninfected control cells and cells
infected with lentivirus particles carrying either shRNA
direct against PDE4D or nonsense shRNA grew at similar
rates. Cells treated with PDGF were increased by almost
threefolds when compared to untreated cells. Infection
of VSMCs with lentivius particles carrying shRNA direct
against PDE4Dsigniﬁcantly resulted in about30%reduction
of PDGF-induced proliferation. In contrast, infection of
VSMCswiththelentivirusparticlecarryingnonsense shRNA
did not signiﬁcantly aﬀectPDGF-induced proliferation. This
result demonstrates an important role of PDE4D in PDGF
directed VSMC proliferation.
3.3. PDE4D Gene Silence Suppresses Migration. To determine
whether PDE4D gene contributes to VSMC migration, we
silenced gene expression using lentivirus particle carrying4 Stroke Research and Treatment
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Figure 2: PDE4D regulates PDGF-induced VSMC proliferation.
VSMC viability was determined using MTT assay at 48 hours
postinfection. Data are mean ± SEM of 3 separate experiments
performed in triplicate. ∗P less than .05 versus control. #P less
than .05 versus nonsenseshRNA.
shRNA against PDE4D and evaluated migration using Boy-
den’s chamber. Rat aortic VSMCs were made quiescent by
24 hour treatment in serum-free culture medium. As shown
in Figure 3, noninfected control cells and cells infected with
lentivirus encoding either shRNA direct against PDE4D or
nonsense shRNA had similar migration rates. Treatment
with PDGF signiﬁcantly increased VSMC migration up
to sixfolds when compared to untreated cells. Infection
o fV S M C sw i t hl e n t i v i r u sp a r t i c l ec a r r y i n gs h R N Ad i r e c t
against PDE4D signiﬁcantly resulted in almost 39% reduc-
tion of PDGF-induced migration. In contrast, infection of
VSMCs with thelentivirus carrying nonsense shRNA did not
signiﬁcantly aﬀect PDGF-induced migration.
3.4. Intracellular cAMP Level. To examine whether the
inhibitory eﬀects of PDE4D gene silence on VSMC prolif-
eration and migration were mediated through intracellular
cAMP, we measured cAMP levels by enzyme immunoassay
after infection of VSMCs with lentivrus carrying shRNA
against PDE4D gene (Figure 4). Infection of VSMCs with
lentivrus particle carrying either shRNA against PDE4D
gene or nonsense shRNA did not result in any signiﬁcant
change in VSMC basal level of cAMP. The addition of PDGF
(20ng/mL) stimulated a statistically signiﬁcant accumula-
tion of cAMP in VSMCs compared with control. However,
infection of VSMCs with lentivirus particle carrying shRNA
against PDE4D gene or nonsense shRNA did not result in
any signiﬁcant change in PDGF-stimulated accumulation of
cAMP.
4.Discussion
In the present study, we studied the functional consequence
of PDE4D knockdown by RNA interference in PDGF-
induced VSMC proliferation and migration. We found that
knockdown of endogenous PDE4D signiﬁcantly reduces
rat aortic VSMC proliferation and migration. However,
the inhibition does not lead to alteration of the global
intracellular cAMP level,suggesting that the inhibition is less
likely mediated through cAMP.
Atherosclerosis is a major cause of ischemic stroke
[27]. Vascular endothelial cell injury and subsequent migra-
tion and proliferation of VSMCs are early key events of
atherosclerosis. We here used cultured VSMCs after three
passages as a model to study VSMC proliferation and migra-
tion because they represent VSMCs in a synthetic phenotype
which is similar to migrating smooth muscle cells in vivo.
Platelet-derived growth factor (PDGF), one of the most
potent mitogens and chemoattractants for VSMCs produced
by platelets, VSMCs, and endothelial cells in the injured vas-
cularwall,playsthecentralroleintheonsetanddevelopment
ofvasculardisorders[28,29].Therefore,VSMCproliferation
and migration in this study were induced by the addition
of the potent and pathophysiologically relevant chemotactic
factor PDGF.As shown in Figure 2,w ec o n ﬁ r m e dt h a tP DG F
caused proliferation in rat VSMC s .I na d d i t i o n ,w eo b s e r v e d
about 30% reduction of PDGF-induced cell proliferation in
PDE4D deﬁcient VSMCs. We believe that the reduction of
PDGF-induced cell proliferation inPDE4D deﬁcient VSMCs
is speciﬁc because knockdown of PDE4D had no eﬀect on
quiescent VSMCs where PDGF was absent. This ﬁnding is
consistent with previous studies that Rolipram, a general
PDE4 inhibitor, can inhibit proliferation of VSMCs from
26% to 37 ± 6% [30–32]. It is not surprised to note that
knockdown of PDE4D did not achieve a full suppression
of VSMC proliferation because multiple signals are involved
in PDGF-induced VSMC proliferation. Furthermore, the
members of PDE family in addition to PDE4D have been
shown to closely associate with VSMC proliferation. For
example, inhibition of PDE3 and PDE1A also reduce VSMC
proliferation [33, 34]. Nevertheless, our data suggest that
PDE4D is important in PDGF-induced VSMC proliferation.
Although VSMC migration plays a pivotal role in the
pathogenesis of arteriosclerosis, the role of PDE4D in VSMC
migration has receivedmuchless attention.Fewinvestigators
have studied the eﬀects of PDE4D on VSMC migration. The
results are inconsistent in those limited reports. Forexample,
Goncharova and his colleagues found that cilomolast, a
PDE4 inhibitor can inhibit basal (unstimulated) and PDGF-
stimulated migration of airway smooth muscle and pul-
monary vascular smooth muscle cells [35]. Palmer and his
colleaguesreported thatRo20-1724,anotherPDE4 inhibitor
with potent eﬀect on PDE4D, potentiated antimigratory
eﬀect caused by forskolin [25]. However, neither cilomolast
nor Ro 20-1724 is the speciﬁc inhibitor against PDE4D.
As a result, lack of selective inhibitors against PDE4D
makes it diﬃcult to determinate the functional roles of
P D E 4 Di s o f o r m .T oo v e r c o m et h i sp r o b l e m ,w eu s e ds h R N A
techniques to selectively knockdown PDE4D expression in
VMSCs. We found that knockdown of PDE4D signiﬁcantly
inhibited PDGF-induced migration. This eﬀect is in parallel
to the inhibitory action of PDE4D on VMSC proliferation.
It has been well documented that cAMP and its sig-
naling play a critical role in regulating VSMC proliferation
and migration [21, 22, 36]. In addition, cAMP is the
only substrate of PDE4D. Therefore, we hypothesized that
the inhibitory eﬀects of knockdown of PDE4D might be
mediated through its regulation of cAMP. Although PDGF-
inducedrobustproductionofcAMPinVMSCcells,wefailedStroke Research and Treatment 5
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Figure 3: Knockdown of endogenous PDE4D inhibits PDGF-induced VSMC migration. PDGF-induced VSMC migration was assessed in
a Boyden’s chamber. Representative images (a, b, c) and group data (d) are shown. (a)–(c) Representative photomicrographs illustrating
migration of VSMCs. (a) Migration of VSMCs stimulated by PDGF-BB. (b) Migration of VSMCs stimulated by PDGF-BB in cells infected
withlentivirus particles carryingnonsenseshRNA.(c)MigrationofVSMCsstimulatedby PDGF-BB incells infected withlentivrius carrying
shRNA againstPDE4D. (d) Bar graph illustratingPDGF-BB-induced VSMCmigration in noninfected cells and cells infected with lentivirus
particles carrying either PDE4D or nonsenseshRNA. Numbers of migrated VSMCs were much less in cells infected with lentivrius carrying
PDE4D shRNA compared with noninfected cells or cells infected with lentivirus particles carrying nonsenseshRNA. Bars are the mean plus
minus SEM of six random ﬁelds of view from three separate experiments. Original magniﬁcation, ×400. ∗P less than.05 versus control. #P
less than.05 versus nonsenseshRNA.
to detect any signiﬁcant change of cAMP level in PDGF-
induced PDE4D deﬁcient VMSC which is consistent with
several previous reports [28, 29]. Given that intracellular
cAMP level is modulated by PDE family members, it is
reasonable that inhibition of PDE4 or PDE4D alone may
n o tb ea b l et oa ﬀect the global level of cAMP in cells. The
other possible explanation is that the eﬀect of PDE4 family
on VSMC proliferation and migration may not be entirely
mediated by change in intracellular cAMP concentration. In
addition to its action on cAMP-signaling, PDE4D also has a
cross-talk with extracellular-signal-regulated kinases (ERK)
in response to both cAMP-dependent and non-cAMP-
dependent agents. ERK has been reported to be important
for PDGF- stimulated proliferation and migration of VSMC.
In addition, cAMP are distributed with spatial gradient,
not freely [37, 38]. Therefore, cAMP induced by PDE4 or
other family member can be highly compartmentalized and
insuﬃcient to increase total cellular cAMP. This may also
explain the failure to detect a signiﬁcant change in cAMP
after single inhibition of PDE4. Therefore, we speculate
that knockdown of PDE4D may alter local concentration
of cAMP and thus regulate its signaling locally to inhibit
proliferation and migration of cells.
5.Conclusion
In this study, we infect VSMC with lentivrius particles
carrying shRNAdirectagainst PDE4D.Consequently,VSMC6 Stroke Research and Treatment
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Figure 4: Knockdown of endogenous PDE4D does not aﬀect
PDGF-induced cAMP level in VSMC. Bar graph illustrates PDGF-
BB induced cAMP level in noninfected cells and cells infected with
lentivirus particles carrying either PDE4D or nonsense shRNA.
There were no signiﬁcant diﬀerences in cAMP level between cells
infected with lentivrius carrying PDE4D shRNA and noninfected
cells, cells infected with lentivirus particles carrying nonsense
shRNA. Values represent means ± SEM from three separate
experiments.∗P less than.05 versus control.
proliferation and migration was signiﬁcantly inhibited, and
the inhibitory eﬀects were not associated with global intra-
cellularcAMPlevel.OurresultsimplicatethatPDE4Dhasan
important role in VSMC proliferation and migration which
may explain its genetic susceptibility to ischemic stroke.
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